Systolic Hypertension in the Elderly Program (SHEP)

Introduction .................................................................................................................. II-1

Part 1: Rationale and Design
Nemat O. Borhani, William B. Applegate, Jeffrey A. Cutler, Barry R. Davis, Curt D. Furberg,
Edward Lakatos, Lot Page, H. Mitchell Perry, W. McFate Smith, and Jeffrey L. Probstfield ........ II-2

Part 2: Screening and Recruitment
Helen Petrovitch, Robert Byington, Geri Bailey, Patty Borhani, Sharon Carmody, Laretha Goodwin,
Joseph Harrington, H. Arleen Johnson, Phillip Johnson, Melissa Jones, Julie Levin, Carolyn Sugars,
and Jeffrey L. Probstfield ................................................................................................ II-16

Part 3: Sociodemographic Characteristics
Thomas M. Vogt, Eleanor Schron, Sara Pressel, Sylvia Wasserthiel-Smoller, E.E. Eddleman,
Stephen Miller, and Jeremiah Stamler ........................................................................... II-24

Part 4: Baseline Medical History Findings

Part 5: Baseline Blood Pressure and Pulse Rate Measurements
Darwin R. Labarthe, M. Donald Blaufox, W. McFate Smith, Clifton R. Lacy, Harold Schnaper,
Frances LaBaw, Steven Masiocchi, Janice Davey, and Edward Lakatos ............................... II-62

Part 6: Baseline Physical Examination Findings
Henry R. Black, Deanne Unger, Alfredo Burlando, John C. Wright, Sara L. Pressel, Ralph Allen,
Robert H. McDonald, and Hemantha Surath .................................................................. II-77

Part 7: Baseline Laboratory Characteristics
W. Dallas Hall, Barry R. Davis, Philip Frost, Mary Hoffmeier, Joseph E. O'Brien, Susan Pace, Lot Page,
Kenneth A. Schneider, and Jeremiah Stamler ............................................................... II-102

Part 8: Electrocardiographic Characteristics
John B. Kostis, Ronald Prineas, J. David Curb, Marshall Lee, David Berkson, Jeffrey Raines,
William Frishman, Charles K. Francis, and Thomas Sheffield ........................................ II-123

Part 9: Behavioral Characteristics
Philip G. Weiler, Greta H. Camel, Margaret Chiappini, Merwyn R. Greenlick, Glenn H. Hughes,
Judith Challop Luhr, Lemuell A. Moyé, Dan Mungas, Mary Perron, Michael H. Peters, Thomas R. Price,
Eleanor Schron, and Richard B. Shekelle ....................................................................... II-152

Part 10: Analysis
Janet Wites, Barry Davis, Kenneth Berge, Jerome D. Cohen, Richard H. Grimm Jr., C. Morton Hawkins,
and Lewis Kuller ............................................................................................................ II-162

Acknowledgments ......................................................................................................... II-168

HYPERTENSION (ISSN 0194-911X) is published monthly by the American Heart Association, 7320 Greenville Avenue, Dallas, TX 75231-4599. For rates in Japan, contact Nankodo Co., Ltd., 42-6 Hongo 3-chome, Bunkyo-ku, Tokyo 113, Japan. In the United States, individuals may subscribe for their personal use at the following annual rates: $76 for members of an American Heart Association scientific council and $96 for nonmembers. Outside the United States, add $34 for postage. Contact AHA for single copy rates and subscription rates for medical professionals in training and for libraries, reading rooms, and other multiple-use institutions. Second class postage paid at Dallas, Texas, and additional mailing offices. POSTMASTER: Send address changes to HYPERTENSION, American Heart Association, 7320 Greenville Avenue, Dallas, TX 75231-4599.
Supplement to Hypertension

Systolic Hypertension in the Elderly Program (SHEP)

Expanded Table of Contents

Introduction ............................................. II-1
Part 1: Rationale and Design ................................ II-2
  Isolated Systolic Hypertension
  Prevalence of Isolated Systolic Hypertension
  Mortality Risks with Isolated Systolic Hypertension
  Historical Background of SHEP
    SHEP Pilot Study
      Objectives; Recruitment; Adherence; Diuretic efficacy; Adverse effects; Behavioral assessment; End point determination
    Transition From SHEP Pilot Study to SHEP Trial
  SHEP Trial
    Objectives
      Primary hypothesis; Secondary objectives; Subgroup hypotheses
    Other Aspects of SHEP Design
      Power calculations and sample size for the primary hypothesis; Power calculations for the two subgroup hypotheses; Entry criteria; Inclusion criteria; Exclusion criteria; Choice of antihypertensive medications; Recruitment, including initial contact, and baseline visits for identification, evaluation, and enrollment of eligible participants; Randomization; Treatment program; Follow-up procedures; Monitoring for "escape" blood pressure levels and other possible adverse effects; Behavioral evaluation; Determination of nonfatal and fatal trial end points
    Governance, Organization, and Administration
  Conclusion
  References

Part 2: Screening and Recruitment ................................ II-16

Methods
  Goals of Recruitment
  Recruitment Personnel
  Recruitment Strategies
    Public relations measures; Mail campaigns; Mass screening; Chart review
  Screening Procedures
    Prescreening; Initial contact, drug evaluation, and baseline visits
  Randomization

Results
  Recruitment Pattern by Calendar Time Period
  Total Initial Contact Visits, Baseline Visits, and Randomizations by Center
  Reasons for Ineligibility at Baseline Visits 1 and 2

Discussion
  Problems With Recruitment
  Suggestions for Future Collaborative Trials
  References

Part 3: Sociodemographic Characteristics ................................ II-24

Methods

Results
  Summary of Sociodemographic Characteristics of SHEP Randomized Participants
  Age, Race, Sex, Baseline Systolic Blood Pressure, and Use of Antihypertensive Medication at Screening
  Clinical Center, Age, Race, and Sex
  Age, Race, Sex, Marital Status, and Activity Limitation
  Age, Race, Sex, Education, and Employment Status
  Marital Status, Activity Limitation, Education, and Ethnicity
Age, Race, Sex, and Smoking and Drinking Practices
Sociodemographic Characteristics of Volunteers for SHEP at Baseline Visits 1 and 2 and Randomization and Comparisons With the US Population

References

Part 4: Baseline Medical History Findings ........................................... II-35

Methods

Results

Number and Percentage of Randomized SHEP Participants
Baseline Medical History Findings for Entire Cohort
Cardiovascular History
  Hypertension; Heart attack; Stroke; Vascular surgery
Gastrointestinal History
  Ulcer; Colitis; Liver disease
Endocrine History
  Diabetes; Gout
Genitourinary History
  Kidney; Prostate
History of Falls and Fracture
  Frequent falls; Hip fracture; Spine fracture; Forearm fracture
Cancer History, Any Site
Other Findings From Past History
  Arthritis; Lung problems
Hospitalization Within 5 Years
Reported Symptoms and Related Diagnoses at Baseline Relevant to Trial End Points
  Angina pectoris; Possible myocardial infarction; Possible transient ischemic attack or stroke; Possible intermittent claudication
Reported Gastrointestinal Symptoms at Baseline Possibly Related to Subsequent Side Effects of Drug Treatment
  Recurrent stomach pains; Black or tarry stools; Recent blood in stools
Possible Cerebrovascular Symptoms Reported at Baseline
  Severe headache; Faintness on standing quickly; Blacking out or losing consciousness
Other Symptoms Reported at Baseline
  Orthopnea; Shortness of breath with exertion

Part 5: Baseline Blood Pressure and Pulse Rate Measurements ........................................... II-62

Methods

Results

Summary Data: Mean Values for All Randomized Participants
Systolic Blood Pressure at Baseline Visit 1
Systolic Blood Pressure at Baseline Visit 2
Systolic Blood Pressure: Baseline Level
Diastolic Blood Pressure at Baseline Visit 1
Diastolic Blood Pressure at Baseline Visit 2
Diastolic Blood Pressure: Baseline Level
Mean Arterial Pressure at Baseline Visit 2
Pulse Pressure at Baseline Visit 2
Standing Systolic Blood Pressure and Differences Between Sitting and Standing Systolic Blood Pressures at Baseline Visit 2
Pulse Rate at Baseline Visit 2

Part 6: Baseline Physical Examination Findings ........................................... II-77

Methods

Results

Overall Findings
Sample Size and Anthropometric Measurements
  Sample size; Weight; Height; Body mass index
Ocular Fundi
  Fundi visualized; Abnormal fundi
Neck
  Carotid bruits; Carotid bruits—Unilateral; Carotid pulses—Absent or diminished
Chest and Lungs
  Bilateral rales; Wheezing
Heart
  Any murmur; Point of maximal cardiac impulse more than 2 cm lateral to midclavicular line; Third heart sound; Fourth heart sound; Irregular pulse
Abdominal Bruits
Extremities
- Pitting ankle edema; Femoral bruit; Peripheral pulses—Diminished or absent
- Overall Freedom From Abnormalities, Including Neurological Abnormalities

References

Part 7: Baseline Laboratory Characteristics .......................................................... II-102
Methods
  Procedures
  Quality Control
Results
- Number of Randomized Participants and Mean Value for Each Variable
- Sample for Measurements
- Serum Glucose
- Serum Total Cholesterol
- Serum High Density Lipoprotein Cholesterol
- Serum Triglycerides
- Serum Uric Acid
- Serum Calcium
- Serum Alkaline Phosphatase
- Serum Blood Urea Nitrogen and Creatinine
- Serum Potassium
- Hematocrit
- Serum γ-Glutamyl Transpeptidase
References
Appendix
- Measurement of Serum Glucose
- Measurement of Serum Uric Acid
- Measurement of Serum Cholesterol
- Measurement of Serum Triglycerides
- Venipuncture Protocol

Part 8: Electrocardiographic Characteristics ....................................................... II-123
Methods
Results
- Overall Findings
- Q/QS Patterns
- T Wave Findings
  - Moderate abnormalities; Minor abnormalities; Average T amplitude in Lead V5
- Negative U Wave
- ST Depression—Moderate or Minor
- AV Conduction Defects
  - Prolonged PR interval; Short PR interval
- Ventricular Conduction Defects
  - Complete left bundle branch block; Complete right bundle branch block; Incomplete right bundle branch block; RR' patterns
- Left Axis Deviation—QRS Axis of −30° or Less
- Left Ventricular Hypertrophy
  - "Hard" left ventricular hypertrophy; Moderate left ventricular hypertrophy
- High-Amplitude R Waves
  - Marked left high-amplitude R waves; Moderate left high-amplitude R waves; Average R amplitude in lead aVL
- Left Atrial Hypertrophy
- Premature Beats
  - Any supraventricular premature beats; Any ventricular premature beats
  - on 2-minute rhythm strip
- Codable Items of Low Prevalence
  - One or More Codable Findings
- Average Heart Rate
References

Part 9: Behavioral Characteristics ......................................................................... II-152
Methods
Part I
  - The SHEP SHORT-CARE; Center for Epidemiological Studies Depression Scale; Physical Functioning and Activities of Daily Living Questionnaire; Social Network Questionnaire
Part II
  - Quality-of-Life Questionnaire; Trail Making Test; Digit Symbol Substitution Test; Addition Test; Finding the A's Test; Boston Naming Test; Delayed Recognition Span Test; Letter Sets Test
Results
Part I
The SHEP SHORT-CARE; Center for Epidemiological Studies Depression Scale; Physical Functioning and Activities of Daily Living scales; Social Network Index
Part II
Quality-of-Life Questionnaire; Trail Making Test—Parts A and B; Digit Symbol Substitution Test; Addition Test; Finding the A's Test; Boston Naming Test; Delayed Recognition Span Test; Letter Sets Test
References
Part 10: Analysis ........................................................................... II-162
Power for the Primary End Point
Sample Size
Person-Years of Follow-up
Adherence
Power
Secondary Objectives
Analyses That Do Not Preserve the Randomization
Monitoring SHEP Data
Summary
References
Acknowledgments ....................................................................... II-168